Journal
LEUKEMIA
Volume 35, Issue 1, Pages 189-200Publisher
SPRINGERNATURE
DOI: 10.1038/s41375-020-0810-4
Keywords
-
Categories
Funding
- National Institutes of Health [P30CA033572, NIH-2-R01-CA201382, NIH-2-R01-CA238429-01]
- Steven Gordon and Briskin Family Innovation Grant
Ask authors/readers for more resources
Despite the reduction of NK cells during Dara therapy, they play a pivotal role in the anti-MM activity of Dara. Targeting CD38+ NK cells by Dara also promotes monocyte activation and enhances anti-MM phagocytosis activity. In MM patients who discontinued Dara therapy, targetable unmutated surface CD38 expression is maintained on MM cells, while effector cells with impaired cellular immune function remain.
Daratumumab (Dara), a multiple myeloma (MM) therapy, is an antibody against the surface receptor CD38, which is expressed not only on plasma cells but also on NK cells and monocytes. Correlative data have highlighted the immune-modulatory role of Dara, despite the paradoxical observation that Dara regimens decrease the frequency of total NK cells. Here we show that, despite this reduction, NK cells play a pivotal role in Dara anti-MM activity. CD38 on NK cells is essential for Dara-induced immune modulation, and its expression is restricted to NK cells with effector function. We also show that Dara induces rapid CD38 protein degradation associated with NK cell activation, leaving an activated CD38-negative NK cell population. CD38+ NK cell targeting by Dara also promotes monocyte activation, inducing an increase in T-cell costimulatory molecules (CD86/80) and enhancing anti-MM phagocytosis activity ex vivo and in vivo. In support of Dara's immunomodulating role, we show that MM patients that discontinued Dara therapy because of progression maintain targetable unmutated surface CD38 expression on their MM cells, but retain effector cells with impaired cellular immune function. In summary, we report that CD38+ NK cells may be an unexplored therapeutic target for priming the immune system of MM patients.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available